OncoMatch/Clinical Trials/NCT06616571
Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints
Is NCT06616571 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including QL0605(PEG-rhG-CSF) and QL0605(PEG-rhG-CSF) for chemotherapy-induced febrile neutropenia.
Treatment: QL0605(PEG-rhG-CSF) · QL0605(PEG-rhG-CSF) — The goal of this real-world study is to compare the efficacy and safety of QL0605 administered 24 hours and 48 hours after chemotherapy in breast cancer patients.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
Cannot have received: radiation therapy
Cannot have received: peg-rhg-csf
Lab requirements
Blood counts
good hematology
Kidney function
good kidney function
Liver function
good liver function
Subjects with good hematology, liver, lung and kidney function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify